Core Viewpoint - Stock Yards Bancorp, Inc. will participate in the Stephens Investor Conference on June 16 and 17, 2025, in Portland, Maine, engaging in one-on-one meetings with institutional investors [1][2]. Company Overview - Stock Yards Bancorp, Inc. is based in Louisville, Kentucky, and has $9.00 billion in assets [2]. - The company was incorporated in 1988 as a bank holding company and is the parent of Stock Yards Bank & Trust Company, which was established in 1904 [2]. - The common shares of the company trade on The NASDAQ Stock Market under the symbol "SYBT" [2]. Conference Participation - Key executives participating in the conference include Ja Hillebrand (Chairman and CEO), Phil Poindexter (President), and T. Clay Stinnett (EVP and CFO) [1]. - Management's discussion materials for the conference will be available on the company's investor section of the website on or before June 16, 2025 [2].

Core Insights - Rigetti Computing has completed sales of $350 million in gross proceeds from its common stock through an at-the-market equity offering program, bringing its total cash, cash equivalents, and available-for-sale investments to approximately $575 million with no debt [1] - The company plans to utilize the proceeds primarily for working capital, capital expenditures, and general corporate purposes, with potential future investments in strategic collaborations, acquisitions, or partnerships [1] Company Overview - Rigetti Computing is a pioneer in full-stack quantum computing, operating quantum computers over the cloud since 2017 and serving a diverse clientele including global enterprises, government, and research institutions through its Rigetti Quantum Cloud Services platform [2] - The company began selling on-premises quantum computing systems in 2021, featuring qubit counts ranging from 24 to 84, and introduced its 9-qubit Novera QPU in 2023 to support the R&D community [2] - Rigetti has developed the industry's first multi-chip quantum processor for scalable quantum computing systems and manufactures its chips in-house at Fab-1, the first dedicated and integrated quantum device manufacturing facility [2]

Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trialBURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced preliminary results from a multicenter, randomized controlled trial titled, “Accelerated Deep TMS for Depression: Results from a Multisite, Randomized Non-Inf ...

QUEBEC CITY, Canada, June 11, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech” or the “Company”) (Nasdaq: LDTC), an AI-powered software company recognized for its innovation in advanced driver assistance systems (ADAS) and autonomous driving (AD), today announces that, as a result of the cessation of the Company’s discussions with a significant potential commercial counterpart and in light of the Company’s current financial position, the Company has laid off most of its employees and will no ...

Juvena Therapeutics is a platform-driven, clinical-stage company unlocking the therapeutic potential of stem- cell secreted proteins and translating them into a growing pipeline of engineered biologics for chronic muscle and metabolic diseases. Juvena is achieving this through its fully integrated, end-to-end Artificial Intelligence (AI)-enabled drug discovery and development platform, JuvNET, that combines a compounding database mapping secreted proteins to specific disease phenotypes, in silico and in vit ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Core Insights - Ocugen, Inc. is set to present at the 2025 BIO International Convention, showcasing its innovative gene therapies for blindness diseases [1][2] - The company has recently executed a binding term sheet for exclusive rights to OCU400 in Korea, indicating a strategic partnership aimed at enhancing its market presence [3] - Ocugen's modifier gene therapy platform has achieved significant milestones, including FDA alignment for a pivotal trial and nearing completion of enrollment for the OCU400 Phase 3 clinical trial, with plans to file a Biologics License Application by mid-2026 [3] Company Overview - Ocugen, Inc. specializes in gene therapies for blindness diseases, focusing on inherited retinal diseases and conditions affecting millions globally, such as retinitis pigmentosa and Stargardt disease [6] - The company's modifier gene therapy platform is designed to address complex diseases caused by imbalances in multiple gene networks, distinguishing it from traditional gene therapies [6] Conference Details - Dr. Shankar Musunuri, Chairman and CEO, will present on June 16, 2025, and participate in panel discussions on optimizing clinical outcomes and navigating the regulatory landscape during the convention [4][5]

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . Analyst's Disclosure:I/we have a beneficial long position in the shares of TPL, LB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha ...

Core Viewpoint - Matador Technologies Inc. has acquired an additional 5.38 bitcoin for CAD$798,000 (USD$581,198), bringing its total Bitcoin holdings to approximately 69 bitcoin, reinforcing its long-term capital preservation strategy [1][2]. Financial Position - The company operates debt-free, with all Bitcoin holdings free and clear, and maintains cash reserves of approximately CAD$6.5 million and physical gold holdings of 2 kilograms (approximately CAD$319,000) [2][3]. - The recent acquisition of Bitcoin was made at an average price of USD$107,217 per bitcoin, inclusive of fees and expenses [1]. Strategic Investments - Matador has committed to invest in HODL Systems, a publicly traded Indian technology company, which would provide up to 24.95% ownership, enhancing its exposure to the global digital asset ecosystem [3][6]. - This investment aligns with the company's goal of deepening its commitment to Bitcoin as a reserve asset and expanding its treasury holdings [6]. Long-term Strategy - The company integrates Bitcoin into its long-term strategy as a core treasury asset and aims to leverage blockchain technology to deliver long-term value for stakeholders [4][5]. - Matador's strategy includes strategic Bitcoin accumulation, product development, and participation in digital asset infrastructure, driving long-term shareholder value without dilution [5].

Myriad Uranium Reports Final Chemical Assays from Copper Mountain. Grades Up to 60% Higher Than Probe Equivalents, with Positive Implications for Scale and Scope of the Project. Plan of Operations Application Submitted to Drill High Priority Prospects June 11, 2025 7:30 AM EDT | Source: Myriad Uranium Corp. Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Myriad Uranium Corp. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) is pleased to report chemical assay results from the final six boreholes drilled in ...